Literature DB >> 20307910

Predictors of acute bowel toxicity in patients treated with IMRT whole pelvis irradiation after prostatectomy.

Lucia Perna1, Filippo Alongi, Claudio Fiorino, Sara Broggi, Mauro Cattaneo Giovanni, Cesare Cozzarini, Nadia Di Muzio, Riccardo Calandrino.   

Abstract

PURPOSE/
OBJECTIVE: Whole pelvis irradiation with IMRT (WPRT-IMRT) after prostatectomy is efficient in reducing acute toxicity: however, a number of patients still experience moderate acute bowel toxicity.
MATERIALS AND METHODS: Ninety-six patients treated with WPRT-IMRT after prostatectomy with adjuvant or salvage intent were analysed. A number of parameters were individually recovered, including the DVHs of the intestinal cavity outside PTV and of the loops referred to both the WPRT phase and the whole treatment. Correlation between clinical-dosimetric parameters and acute bowel toxicity was investigated by logistic analyses. Best predictive cut-off values for continuous variables were assessed by ROC curves.
RESULTS: 15/96 (15.6%) Patients experienced grade 2 toxicity (no grade 3). Best dose-volume predictors were the fraction of loops receiving more than 45, 50 and 55 Gy (respectively, V45TL ≥ 50cc, V50TL ≥ 13cc, V55TL ≥ 3cc; p-values ranging from 0.005 to 0.027). Age, GU acute toxicity, rectal acute toxicity and time between prostatectomy and IMRT were also predictors of acute bowel toxicity. Multivariate analysis showed that the most predictive independent parameters were age (OR: 1.13; 95%CI: 1.02-1.25; p=0.021) and V50TL (≥ 13cc, OR: 8.2; 95%CI: 1.7-40; p=0.009).
CONCLUSIONS: The risk of moderate acute uGI toxicity during WPRT-IMRT for post-operatively treated patients increases with age; the risk is substantially reduced in patients with small overlap between PTV and loops.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20307910     DOI: 10.1016/j.radonc.2010.02.025

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  Toxicity and outcome of pelvic IMRT for node-positive prostate cancer.

Authors:  A-C Müller; J Lütjens; M Alber; F Eckert; M Bamberg; D Schilling; C Belka; U Ganswindt
Journal:  Strahlenther Onkol       Date:  2012-10-11       Impact factor: 3.621

2.  Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?

Authors:  Akram Saad; Jeffrey Goldstein; Yaacov R Lawrence; Benjamin Spieler; Raya Leibowitz-Amit; Raanan Berger; Tima Davidson; Damien Urban; Lev Tsang; Dror Alezra; Ilana Weiss; Zvi Symon
Journal:  Radiat Oncol       Date:  2017-01-06       Impact factor: 3.481

3.  Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer.

Authors:  M R Ferreira; K Thomas; L Truelove; A Khan; C Parker; D P Dearnaley; S Gulliford
Journal:  Clin Oncol (R Coll Radiol)       Date:  2019-03-20       Impact factor: 4.126

4.  A Contouring Strategy and Reference Atlases for the Full Abdominopelvic Bowel Bag on Treatment Planning and Cone Beam Computed Tomography Images.

Authors:  Elizabeth Orton; Elsayed Ali; Keren Mayorov; Colin Brown; Nawaid Usmani; Shilo Lefresne; Michael Peacock; Kristopher Dennis
Journal:  Adv Radiat Oncol       Date:  2022-07-23

5.  A prospective comparison of acute intestinal toxicity following whole pelvic versus small field intensity-modulated radiotherapy for prostate cancer.

Authors:  Yeon Joo Kim; Jin-Hong Park; In-Ha Yun; Young Seok Kim
Journal:  Onco Targets Ther       Date:  2016-03-09       Impact factor: 4.147

Review 6.  Integrating Geriatric Assessment into Decision-Making after Prostatectomy: Adjuvant Radiotherapy, Salvage Radiotherapy, or None?

Authors:  Aurore Goineau; Bénédicte d'Aillières; Laure de Decker; Stéphane Supiot
Journal:  Front Oncol       Date:  2015-10-15       Impact factor: 6.244

7.  Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients.

Authors:  Aurore Goineau; Loïc Campion; Bénédicte d'Aillières; Brigitte Vié; Agnès Ghesquière; Guillaume Béra; Didier Jaffres; Guy de Laroche; Nicolas Magné; Xavier Artignan; Jérôme Chamois; Philippe Bergerot; Etienne Martin; Gilles Créhange; Elisabeth Deniaud-Alexandre; Xavier Buthaud; Yazid Belkacémi; Mélanie Doré; Laure de Decker; Stéphane Supiot
Journal:  PLoS One       Date:  2018-04-09       Impact factor: 3.240

8.  Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?

Authors:  Aurore Goineau; Loïc Campion; Jean-Marie Commer; Brigitte Vié; Agnès Ghesquière; Guillaume Béra; Didier Jaffres; Nicolas Magné; Xavier Artignan; Jérôme Chamois; Philippe Bergerot; Gilles Créhange; Elisabeth Deniaud-Alexandre; Xavier Buthaud; Yazid Belkacémi; Mélanie Doré; Laure De Decker; Stéphane Supiot
Journal:  Cancers (Basel)       Date:  2020-03-09       Impact factor: 6.639

9.  Robust dose planning objectives for mesorectal radiotherapy of early stage rectal cancer - A multicentre dose planning study.

Authors:  Ane L Appelt; Ellen M Kerkhof; Lars Nyvang; Ernst C Harderwijk; Natalie L Abbott; Mark Teo; Femke P Peters; Camilla J S Kronborg; Karen-Lise G Spindler; David Sebag-Montefiore; Corrie A M Marijnen
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2019-10-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.